Inhibikase Therapeutics Files 8-K
Ticker: IKT · Form: 8-K · Filed: Oct 9, 2024 · CIK: 1750149
Sentiment: neutral
Topics: 8-K, SEC Filing, Regulation FD
TL;DR
Inhibikase filed an 8-K, but no juicy details yet.
AI Summary
Inhibikase Therapeutics, Inc. filed an 8-K on October 9, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific details on new events, financial figures, or material agreements within the provided text.
Why It Matters
This filing indicates routine corporate reporting to the SEC, but the provided text lacks specific details about significant events or financial updates.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for reporting purposes and does not disclose any new risks or material adverse information.
Key Players & Entities
- Inhibikase Therapeutics, Inc. (company) — Registrant
- October 9, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 001-39676 (commission_file_number) — SEC File Number
- 26-3407249 (irs_number) — IRS Employer Identification No.
- 3350 Riverwood Parkway SE, Suite 1900 (address) — Principal Executive Offices
- Atlanta (city) — Principal Executive Offices
- Georgia (state) — Principal Executive Offices
- 30339 (zip_code) — Principal Executive Offices
- (678) 392-3419 (phone_number) — Registrant's Telephone Number
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report a Regulation FD Disclosure and to file Financial Statements and Exhibits.
What is the exact name of the company filing this report?
The exact name of the company filing this report is Inhibikase Therapeutics, Inc.
On what date was the earliest event reported in this filing?
The earliest event reported in this filing was on October 9, 2024.
In which state was Inhibikase Therapeutics, Inc. incorporated?
Inhibikase Therapeutics, Inc. was incorporated in Delaware.
What is the principal executive office address for Inhibikase Therapeutics, Inc.?
The principal executive office address for Inhibikase Therapeutics, Inc. is 3350 Riverwood Parkway SE, Suite 1900, Atlanta, Georgia 30339.
Filing Stats: 543 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2024-10-09 08:40:04
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value IKT The Nasdaq Stock Mark
Filing Documents
- d882180d8k.htm (8-K) — 26KB
- d882180dex991.htm (EX-99.1) — 42KB
- g882180ex99_1p10g1.jpg (GRAPHIC) — 317KB
- g882180ex99_1p11g1.jpg (GRAPHIC) — 248KB
- g882180ex99_1p12g1.jpg (GRAPHIC) — 422KB
- g882180ex99_1p13g1.jpg (GRAPHIC) — 498KB
- g882180ex99_1p14g1.jpg (GRAPHIC) — 244KB
- g882180ex99_1p15g1.jpg (GRAPHIC) — 312KB
- g882180ex99_1p16g1.jpg (GRAPHIC) — 210KB
- g882180ex99_1p17g1.jpg (GRAPHIC) — 304KB
- g882180ex99_1p18g1.jpg (GRAPHIC) — 225KB
- g882180ex99_1p19g1.jpg (GRAPHIC) — 263KB
- g882180ex99_1p1g1.jpg (GRAPHIC) — 324KB
- g882180ex99_1p20g1.jpg (GRAPHIC) — 340KB
- g882180ex99_1p21g1.jpg (GRAPHIC) — 302KB
- g882180ex99_1p22g1.jpg (GRAPHIC) — 232KB
- g882180ex99_1p23g1.jpg (GRAPHIC) — 367KB
- g882180ex99_1p24g1.jpg (GRAPHIC) — 421KB
- g882180ex99_1p25g1.jpg (GRAPHIC) — 442KB
- g882180ex99_1p26g1.jpg (GRAPHIC) — 318KB
- g882180ex99_1p27g1.jpg (GRAPHIC) — 244KB
- g882180ex99_1p28g1.jpg (GRAPHIC) — 204KB
- g882180ex99_1p29g1.jpg (GRAPHIC) — 371KB
- g882180ex99_1p2g1.jpg (GRAPHIC) — 500KB
- g882180ex99_1p30g1.jpg (GRAPHIC) — 456KB
- g882180ex99_1p31g1.jpg (GRAPHIC) — 258KB
- g882180ex99_1p32g1.jpg (GRAPHIC) — 345KB
- g882180ex99_1p33g1.jpg (GRAPHIC) — 247KB
- g882180ex99_1p3g1.jpg (GRAPHIC) — 372KB
- g882180ex99_1p4g1.jpg (GRAPHIC) — 331KB
- g882180ex99_1p5g1.jpg (GRAPHIC) — 349KB
- g882180ex99_1p6g1.jpg (GRAPHIC) — 270KB
- g882180ex99_1p7g1.jpg (GRAPHIC) — 258KB
- g882180ex99_1p8g1.jpg (GRAPHIC) — 251KB
- g882180ex99_1p9g1.jpg (GRAPHIC) — 350KB
- 0001193125-24-234814.txt ( ) — 14806KB
- ikt-20241009.xsd (EX-101.SCH) — 3KB
- ikt-20241009_lab.xml (EX-101.LAB) — 18KB
- ikt-20241009_pre.xml (EX-101.PRE) — 11KB
- d882180d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Number Description 99.1 Company Presentation 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 9, 2024 INHIBIKASE THERAPEUTICS, INC. By: /S/ MILTON H. WERNER Milton H. Werner, Ph.D. President and Chief Executive Officer